Calypte Biomedical Corp. said that it has raised $6.3 million inan offering of preferred stock to a group of private investorsand venture funds. Investors include Quest Ventures, IndosuezVentures, Technology Partners and Matuschka VenturePartners.
The Berkeley, Calif., company raised $1.5 million in its firstventure round in March 1991.
Calypte's initial product, a diagnostic test for HIV-1 antibodiesin urine, is in clinical trials.
(c) 1997 American Health Consultants. All rights reserved.